CHIKV VLP Vaccine
Prevention of chikungunya virus infection
Phase 3Active
Key Facts
Indication
Prevention of chikungunya virus infection
Phase
Phase 3
Status
Active
Company
About Emergent BioSolutions
Emergent BioSolutions is a publicly traded biopharmaceutical company specializing in medical countermeasures against public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious diseases. The company operates through a fully integrated model encompassing development, manufacturing, and commercialization. Its portfolio includes FDA-approved products for anthrax, smallpox, botulism, and opioid overdose, positioning it as a critical partner to governments worldwide. Emergent's strategic focus is on preparedness and rapid response capabilities for health security emergencies.
View full company profileTherapeutic Areas
Other Prevention of chikungunya virus infection Drugs
| Drug | Company | Phase |
|---|---|---|
| VLA1553 | Bavarian Nordic | Phase 3 |